Wenzhou Celecare Medical Instruments Co.,Ltd , https://www.celecaremed.com
The WuXi PharmaTech Biopharmaceutical R&D Service Center consists of a biopharmaceutical discovery center, a development center, and a cGMP clinical sample base. The Biopharmaceutical Discovery Center will work with OMT (Open Monoclonal Technology) to help customers around the world develop conventional monoclonal antibodies and bispecifics through OMT's advanced all-human monoclonal antibody platform OmniRatTM and WuXi PharmaTech's proprietary phage display library. Sexual monoclonal antibodies as well as antibody-conjugated drugs. The Biopharmaceutical Development Center uses the CHO cell line platform with WuXi PharmaTech's proprietary intellectual property rights, and its advanced flow and perfusion processes can meet a variety of demanding process requirements. The cGMP clinical sample base will be equipped with three 2000-liter flow-adding processes and two 500-liter perfusion bioreactors for the preparation of four clinical samples. By integrating the needs of biopharmaceutical discovery, development and sample preparation, the new R&D service center will provide a more efficient, efficient and fast service for the innovative biopharmaceutical development of WuXi PharmaTech's global customers.
“WuXingkang’s continued investment in biopharmaceutical R&D capacity will better support the rapid growth of R&D business needs of our global customers,†said Dr. Li Ge, Chairman and CEO of WuXi PharmaTech. “The completion of the new center will further strengthen the drug. Mingkang's position in the global biopharmaceutical R&D services sector provides an integrated, innovative R&D solution for the company's global customers."
About WuXi PharmaTech
WuXi PharmaTech is an all-in-one laboratory development and production service company that operates in both China and the United States and provides global pharmaceutical companies, biotechnology companies and medical device companies from drug discovery to marketization. Based on the research and customer-centered mission, WuXi PharmaTech helps customers around the world to shorten the development cycle of drugs and medical devices and reduce R&D costs through a cost-effective and efficient service platform to benefit the global patients.
WuXi PharmaTech Announces Construction of World Biopharmaceutical Integration R&D Center at Shanghai Headquarters
Shanghai, January 11, 2016 - WuXi PharmaTech announced that it has started construction of the world's bio-pharmaceutical integrated R&D service center in the Shanghai headquarters of the company, aiming to provide integrated solutions for global biopharmaceutical discovery, development and clinical production. Promote the development of biopharmaceuticals from innovative ideas to clinical one-stop services. The central project plans a total investment of 120 million US dollars, covers an area of ​​250,000 square feet, and can be built to accommodate 800 scientists. The new center is expected to be completed and put into use in 2017.